该县纪委监委以灵芝深加工健康产业建设为监督切口，聚焦项目审批、资金管理、惠企政策落地、项目 验收等关键环节，紧盯招投标暗箱操作、权钱交易、履职不力等方面问题，对产业发展全过程跟进监 督。深化运用"室组地+职能部门"联动监督力量，通过定期会商、常态调度、及时通报等机制，对中药 材制品生产加工、生物医药成果转化基地、灵芝产品标准化建设等6个重点项目开展监督检查，推动整 改问题15个，处理2人，保障项目建设廉洁高效。 "我们将继续加强对项目运行、资金管理、干部作风等环节的监督检查，及时发现背后的责任、作风和 腐败问题，以有力监督推动乡村振兴特色产业发展成果更多惠及群众。"该县纪委监委有关负责同志 说。（通讯员 韩雪春） 近日，在安徽省旌德县云乐镇灵芝种植基地内，一根根粗壮白胖的灵芝椴木菌棒整齐摆列，三五成群的 工人正手脚麻利地忙着挖坑、搬运、覆土、盖膜。"补贴政策有没有落实到位？农技专家来指导了 吗？"种植基地里，前来走访的云乐镇纪委书记吴万志与种植户面对面交流，详细了解技术管理、种植 规模及补贴等各项政策落实情况。 该县纪委监委还不断强化科技赋能监督，建立大数据模型，对接农业农村、财政、审计、人社等部门， 获取乡 ...

近半年该股累计上榜龙虎榜18次，上榜次日股价平均跌0.98%，上榜后5日平均跌4.89%。 资金流向方面，今日该股主力资金净流入51.91万元，其中，特大单净流入14.98万元，大单资金净流入 36.92万元。近5日主力资金净流入227.85万元。（数据宝） 龙津退今日平盘报收，全天换手率2.27%，成交额554.68万元，振幅5.00%。龙虎榜数据显示，营业部席 位合计净买入22.75万元。 深交所公开信息显示，当日该股因退市整理上榜，营业部席位合计净买入22.75万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交479.34万元，其中，买入成交额为251.05 万元，卖出成交额为228.29万元，合计净买入22.75万元。 具体来看，今日上榜营业部中，第一大买入营业部为广发证券股份有限公司昆明东风西路证券营业部， 买入金额为100.64万元，第一大卖出营业部为广发证券股份有限公司昆明广福路证券营业部，卖出金额 为99.56万元。 龙津退6月24日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | ...

Core Views - Jiangsu Kangyuan Pharmaceutical Co., Ltd. announced the resignation of Chairman Xiao Wei due to personal reasons, while he will continue to serve as a board member and committee chair [1][2] - The company has faced significant performance pressure in recent years, with a notable decline in revenue and net profit [3][5] Management Changes - Xiao Wei, the founder and actual controller of Kangyuan Pharmaceutical, has been a pivotal figure since 2000, leading the company through modernization and successful public listing [1][2] - The legal representative has been changed to Gao Haixin, who has been with the company since 2014 and has held various leadership roles [2] Financial Performance - In 2024, Kangyuan Pharmaceutical reported a revenue of 3.898 billion yuan, a year-on-year decrease of 19.86%, and a net profit of 392 million yuan, down 15.58% [3] - This marks the first decline in performance since 2021, attributed to increased market competition and stricter healthcare policies [3] Product and Market Dynamics - The company's core products, including the Heat Poisoning Injection and Ginkgo Biloba Injection, have seen declining sales due to market pressures [3] - New product lines are being developed, but their performance has not compensated for the losses from core products [3] Acquisition and Future Outlook - In 2024, Kangyuan Pharmaceutical completed a 100% acquisition of Zhongxin Pharmaceutical, enhancing its presence in the biopharmaceutical sector [4] - However, the acquisition comes with risks, including significant debt and ongoing financial commitments for research and development [5] - The company reported a continued decline in Q1 2025, with revenue of 878 million yuan, down 35.38%, and net profit of 83.41 million yuan, down 38.37% [5]

Core Insights - The article highlights the significant development and potential of the Tianma industry in Guizhou Province, emphasizing its role in economic growth and rural revitalization [1][4][9] Industry Development - Guizhou has established itself as the leading region for Tianma cultivation in China, with a history of artificial planting dating back to the 1970s, resulting in a comprehensive industrial chain [2][3] - The province has set a target to develop a 10 billion yuan Tianma industry cluster by 2030, focusing on quality improvement, brand cultivation, and standardized planting [1][4] Technological Innovation - Guizhou University plays a crucial role in advancing Tianma cultivation through research and development, having established a provincial expert team and developed new varieties [5][6] - The province has implemented innovative agricultural techniques to enhance yield and quality, achieving a target of 27 kg of Tianma per square meter [3][6] Economic Impact - The Tianma industry is projected to generate a comprehensive output value of 6.4 billion yuan by 2024, with over 60 counties in Guizhou engaged in Tianma cultivation [4][9] - The industry has created new business entities and improved market competitiveness, benefiting thousands of local farmers [7][8] Brand and Market Expansion - Guizhou is leveraging its unique resources to create a strong brand identity for Tianma, with products tailored to various consumer markets, including ready-to-eat items [8][9] - The establishment of a traceability system from breeding to sales enhances product quality and consumer trust [8][9]

Core Insights - The Xichuan Advanced Manufacturing Development Zone has been recognized as a digital transformation promotion center in Henan Province due to its solid digital infrastructure and innovative transformation practices [1] Group 1: Digital Transformation and Industry Focus - The development zone covers an area of 13.03 square kilometers and hosts 184 enterprises, focusing on digital transformation in four major industry clusters: automotive parts, modern traditional Chinese medicine, new energy, and new materials [1] - The automotive parts industry, led by Xijian, includes 86 associated enterprises with a market share of 20%, primarily producing shock absorbers and various components [2] - The modern traditional Chinese medicine industry, led by Fusen Pharmaceutical, comprises 35 associated enterprises, with market shares of 35.5% for oral solutions and 91.6% for injection solutions of the same product [2] Group 2: Innovation and Support Policies - The development zone has implemented policies to support technological innovation, allocating 50 million yuan in special funds for enterprises, with the automotive parts sector receiving 60 million yuan in provincial R&D support [3] - The area has established a national-level enterprise technology center, three nationally recognized laboratories, and numerous provincial-level centers, with 38 high-tech enterprises and 21 specialized enterprises [3] Group 3: Infrastructure and Investment - The development zone employs a "management committee + company" model for financing and has developed industrial parks for automotive parts, rural revitalization, and immigration, with 390,000 square meters of standardized factories built [4] - In 2024, the 86 large-scale industrial enterprises in the development zone are projected to achieve a total output value of 7.2 billion yuan, accounting for 90% of the county's industrial output, with an industrial added value of 1.83 billion yuan [4]

Group 1 - The core viewpoint of the articles highlights that Jia Ying Pharmaceutical is currently under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact investor confidence and stock performance [2][3] - As of June 20, 2023, Jia Ying Pharmaceutical's financing balance is 248 million yuan, representing 8.17% of its market capitalization, which is below the historical 50th percentile level [2] - The company reported a significant decline in financial performance for 2024, with total operating revenue of 376 million yuan, down 29.46% year-on-year, and a net profit attributable to shareholders of 21 million yuan, down 39.94% year-on-year [3] Group 2 - Investors who purchased Jia Ying Pharmaceutical shares between its listing and May 28, 2025, and still held them at the close on that date, may be eligible for compensation due to the company's alleged information disclosure failures [3] - The company, established in 2003 and a member of the Sheneng Group, is primarily engaged in the pharmaceutical manufacturing industry, specifically in traditional Chinese medicine [3]

2025 年 06 月 24 日 沪深300 及创业板指数近1年走势 数据来源：聚源 昨日涨跌幅前五行业 行业名称 涨跌幅(%) 计算机 2.251 国防军工 1.971 煤炭 1.683 银行 1.220 环保 1.203 数据来源：聚源 开源晨会 0624 ——晨会纪要 吴梦迪（分析师） wumengdi@kysec.cn 证书编号：S0790521070001 观点精粹 总量视角 【宏观经济】工业生产仍有韧性——宏观经济专题-20250623 行业公司 【农林牧渔】消费逐步进入淡季，短期鸡价或有压力——行业点评报告-20250623 【电子】半导体材料跟踪点评：盛合晶微进入辅导验收阶段，关注先进封装材料 投资机会——行业点评报告-20250623 【化工】固态电池产业化进展加速，高性能材料产业化先行——行业点评报告 -20250623 【社服】即时零售 618 大促表现亮眼，5 月茶咖头部品牌开店+店效双高增——行 业周报-20250622 【传媒】AI 模型、端侧齐发力，关注中报及内容新品带来的弹性——行业周报 -20250622 【医药：众生药业(002317.SZ)】夯实中药根基，创新转型乘风破浪 ...

Core Viewpoint - Tong Ren Tang has demonstrated resilience and growth in a complex macroeconomic environment, achieving steady revenue growth and maintaining its position as a leading traditional Chinese medicine enterprise [2]. Financial Performance - In 2024, Tong Ren Tang achieved operating revenue of 18.597 billion yuan, representing a year-on-year increase of 4.12% [2]. - The net profit attributable to shareholders of the listed company saw a decline, but the company managed to maintain growth in operating revenue and net assets through targeted strategies [2]. - The total cash dividend proposed for 2024 is 1.371 billion yuan, accounting for 89.86% of the net profit attributable to shareholders, reflecting the company's commitment to shareholder returns [3]. Marketing and Innovation - The company has implemented marketing reforms by increasing retail outlets, integrating online and offline operations, and expanding medical terminal businesses to enhance market competitiveness [2]. - Tong Ren Tang has increased investment in technological innovation to modernize traditional Chinese medicine, laying a solid foundation for long-term development [2][4]. Governance and Communication - The company continues to improve internal management systems and emphasizes the supervisory role of independent directors to ensure scientific and standardized decision-making [3]. - Management actively engages with investors through regular performance briefings and investor communication events to build trust and confidence [3]. Future Development Strategy - Tong Ren Tang plans to focus on high-quality development in the health sector, enhancing market share and brand influence through marketing reforms and brand building [4]. - The company aims to increase research and development investments, promoting the integration of traditional Chinese medicine with modern technology [4]. - Plans include expanding overseas markets and enhancing international brand influence through partnerships with global pharmaceutical companies [4]. Social Responsibility - The company is committed to sustainable development, increasing environmental investments, and engaging in public welfare activities to support the inheritance and development of traditional Chinese medicine [5]. - Future initiatives will focus on accelerating medical industrial upgrades and digital transformation to enhance productivity [5].

十年磨一剑，今朝展锋芒！在菌钥大健康成立十周年之际，公司再迎高光时刻：经国际知名权威咨询机 构——尚普咨询集团的严格评审，菌钥大健康以科技领先性、产业化规模、行业贡献度、品牌知名度等 全维度优势，正式获评"中药发酵技术全国领导者"称号！这一认证不仅是对企业十年深耕中药发酵领域 的权威背书，更彰显了我国大健康产业在全球竞争中的科技硬实力。 一、引领行业：中药发酵技术全国领导者 作为发酵中药领域的全国领导者与创新引擎，菌钥大健康以"传统组方+现代发酵"双轮驱动模式领跑千 亿赛道，构建从道地药材溯源到智能智造的全产业链闭环。依托20+项与发酵中药相关的国家发明专利 技术与多所知名高校的通力协作，公司打造了极具菌钥特色的中药发酵专利菌株库与"四季养生体系"。 将现代发酵技术与24节气养生相结合，为中医药现代化发展提供了新的思路。 二、认证权威性：尚普咨询——市场调研&品牌认证专家 此次菌钥大健康被认证为"中药发酵技术全国领导者"，是尚普咨询集团从生产口径入手，以能够全面反 映中药发酵产品的生产规模、工艺水平以及市场供应能力等关键信息为主要关键评判标准，通过从销 量、心智两个指标进行深入分析后获得的结果。 该认证标志着 ...

长江商报消息 ●长江商报记者 沈右荣 66岁的肖伟辞职了！ 6月20日晚间，A股公司康缘药业（600557.SH）官宣了这一消息。 肖伟是康缘药业实际控制人，自2000年开始担任公司董事长，至今已有25年。 康缘药业的前身是连云港中药厂。1991年，肖伟临危受命，接任厂长。34年来，肖伟将这家资不抵债、 濒临倒闭的药厂打造成业内知名的中药现代化企业。 肖伟的成功之道，是研发创新。从桂枝茯苓胶囊到热毒宁注射液，再到银杏二萜内酯葡胺注射液，肖伟 通过研发趟出了一条中药创新破局之路。 2021年，62岁的肖伟当选为中国工程院院士，成为医药卫生学部少有的"企业家类型院士"。 依托颇具创新力的产品，康缘药业登陆了A股市场，并创造了归母净利润连续17年增长的骄人业绩。 然而，近年来，医药市场生态突变，康缘药业核心产品滞销，经营业绩下滑。 肖伟不再担任董事长，康缘药业经营承压，谁能力挽狂澜？ 靠一款自研产品起死回生 在中医药界，肖伟创造了传奇，其成就不输以岭药业的创始人吴以岭。 肖伟与吴以岭是南京中医大学校友。公开信息显示，肖伟是山东潍坊人，1959年10月20日出生于江苏省 南京市。1977年至1981年，肖伟进入南京中 ...